Predict your next investment

HEALTHCARE | Medical Devices & Equipment / Surgical Devices
endosense.com

See what CB Insights has to offer

Founded Year

2003

Stage

Acquired | Acquired

Total Raised

$100.6M

Valuation

$0000 

About Endosense

Endosense is a medical technology company focused on improving the efficacy, safety and accessibility of catheter ablation for the treatment of cardiac arrhythmias. The company developed the use of contact-force measurement in catheter ablation with the development of the TactiCath, a force-sensing ablation catheter to give physicians a real-time, objective measure of contact force during the catheter ablation procedure.

Endosense Headquarter Location

Chemin du Grand-Puits 42 Meyrin

Geneva, 1217,

Switzerland

+ 41 22 306 19 60

Latest Endosense News

Medlumics raises €14M in a Series E financing co-led by Asabys Partners, VI Partners and CDTI Innvierte, together with existing investors Andera Partners, Caixa Capital Risc and Innogest

Oct 8, 2020

Madrid, Spain, October 6th 2020: Medlumics, which develops Ablaview®, a unique RF irrigated ablation catheter system that merges photonics and miniaturized optics to guide device placement and directly assess the ablation lesions in real time, announces today the closing of a €14 million Series E financing, co-led by Asabys Partners (through the fund Sabadell Asabys Health Innovation Investments), VI Partners and CDTI Innvierte, with the participation from historical investors Andera Partners, Caixa Capital Risc and Innogest Capital. Several of the investors joining this round were investors in Endosense, a company in the same space acquired by Abbott (St. Jude Medical) in 2013 for more than USD 300 million. Medlumics was founded in Madrid in 2009 and is led by James Greene (CEO) who has long-term experience in the industry both as a serial entrepreneur in the MedTech industry and as an executive in global medical device players. AblaView® is the first imaging system to assess the treatment of Atrial Fibrillation by ablation, allowing the operator to directly assess both the positioning of the ablation catheter on the myocardium and the continuity and transmurality of the ablation. The cardiac Ablation catheter market was $3.9b in 2019, with only 4,4% of people diagnosed being treated using ablation technology. A limiting factor for adoption of the ablation technique remains the high rate of recurrence due to lack of lesion transmurality (ablation of the myocardium in all its depth) and lack of lesion continuity, leaving gaps of untreated tissues. The AblaView® technology tackles this problem, guiding practitioners and confirming therapy success in real time. Ablaview® is fully compatible with the RF ablation catheters that are already on the market. The financing will allow Medlumics to complete the preclinical development of its technology and obtain first in human clinical data. “Medlumics optically guided ablation technology provides electrophysiologists direct information without surrogates to make real time decisions critical for successful ablation resulting in reducing AF recurrence rate. Recent preclinical studies were very successful and demonstrated AblaView®’s ability to directly assess catheter to tissue contact, stability with high sensitivity, and continuous progress of the ablation of the tissue. Using photonics, clinicians will soon directly assess lesion progression and continuity in real time and subsequently locate and ablate gaps with precision. I thank new and existing investors for the trust and support in our company as we will be able to march from preclinical to clinical proof soon”, commented James Greene, CEO of Medlumics SL. Josep Ll. Sanfeliu, Managing Partner at Asabys Partners, said: “We have been following Medlumics for years. We were immediately excited by the last developments of the company and are thrilled to collaborate with a very experienced team at the maturation of a technology that could impact the life of hundreds of thousands of patients worldwide”. Diego Braguglia, Managing Partner at VI Partners, stated: “Medlumics AblaView® will promote RF ablation to the next level, providing real time information on the quality of the ablations. This represents a quantum leap in AF treatment. Patients outcome will be dramatically impacted by the ability of clinicians to follow on real time the progression of the ablations and its quality. We are very honoured and excited to be part of this endeavour.” © 2018 VI Partners AG

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Endosense

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Endosense is included in 2 Expert Collections, including Internet of Things ( IoT ).

I

Internet of Things ( IoT )

3,149 items

M

Medical Devices

7,891 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

Endosense Patents

Endosense has filed 15 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

10/28/2013

3/21/2017

Cardiac arrhythmia, Fiber optics, Surgery, Medical equipment, Digestive system

Grant

Application Date

10/28/2013

Grant Date

3/21/2017

Title

Related Topics

Cardiac arrhythmia, Fiber optics, Surgery, Medical equipment, Digestive system

Status

Grant

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.